Modeling and Simulation - PK/PD Archives | Page 12 of 38 | Certara

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

CertaraJuly 15, 2017

Publication

Interdisciplinary Pharmacometrics Linking Oseltamivir Pharmacology, Influenza Epidemiology and Health Economics to Inform Antiviral Use in Pandemics

CertaraJuly 1, 2017

Publication

Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response

CertaraJune 1, 2017

On-Demand Webinar

Obeticholic Acid—From PK Model to Drug Label

Watch this webinar with Jeffrey Edwards to learn how he used physiologic pharmacokinetic modeling to…

CertaraJune 1, 2017

Blog

Using Pharmacokinetics to Assure Chemical Food Safety

As a veterinarian, I’m responsible for the health and welfare of my animal patients. Sometimes,…

CertaraMay 12, 2017

Publication

Evaluation of Dosing Strategy for Pembrolizumab for Oncology Indications

CertaraMay 1, 2017

Publication

Effect of Disease-related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats

CertaraMay 1, 2017

Publication

Isoniazid Clearance is Impaired Among Human Immunodeficiency Virus/Tuberculosis Patients with High Levels of Immune Activation

CertaraApril 1, 2017

Blog

The Model-informed Precision Dosing Revolution Is Coming

Modeling and simulation (M&S) has been widely accepted and adopted by biopharmaceutical companies and global…

CertaraMarch 7, 2017

Publication

CYP2C9 Genotype-dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites

CertaraMarch 1, 2017

© 2025 Certara. All Rights Reserved. | Privacy policy